Allergy & Immunology

ANCA Vasculitis

Questions discussed in this category

Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?

Does the severity of asthma play a role in decision making?

2 Answers available

Do you utilize cytokine panels to guide treatment of patients with EGPA?

2 Answers available

Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?

1 Answer available

Which ANCA vasculitis patients are better candidates for cyclophosphamide rather than rituximab?

2 Answers available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

1 Answer available

Papers discussed in this category

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Medicine (Baltimore),

The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.

The New England journal of medicine, 2010-07-15

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

Arthritis & rheumatology (Hoboken, N.J.), 2021 Dec 30

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.

European journal of clinical investigation, 2024 Oct 10

Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta-analysis of eight studies.

Clinical and experimental rheumatology, 2019

Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma.

PloS one, 2015 Mar 26

Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss).

Frontiers in immunology, 2022 Jun 10

Serum Proteomic Analysis Identifies SAA1, FGA, SAP, and CETP as New Biomarkers for Eosinophilic Granulomatosis With Polyangiitis.

Rheumatology (Oxford, England), 2025 Mar 01

SERPINA3, FGA, AGP1, ITIH3 and SAA1 as novel biomarkers for eosinophilic granulomatosis with polyangiitis diagnosis and activity assessment.

The Journal of allergy and clinical immunology, 2022 Jun 27

Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.

Related Topics in Allergy & Immunology